PharmaShots | Incisive News in 3 Shots

Subscribe Now

2022

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

June 27, 2022

Gilead Presents 48 Week Results of Hepcludex (bulevirtide) in P-III (MYR301) Trial for the Treatment of Chronic Hepatitis Delta Virus at ILC 2022

Gilead Presents 48 Week Results of Hepcludex (bulevirtide) in P-III (MYR301) Trial for the Treatment of Chronic Hepatitis Delta Vi...

June 24, 2022

Cogent Presents Results of Bezuclastinib in P-II (APEX) Trial for the Treatment of Advanced Systemic Mastocytosis at EHA 2022

Cogent Presents Results of Bezuclastinib in P-II (APEX) Trial for the Treatment of Advanced Systemic Mastocytosis at EHA 2022

June 13, 2022

Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

June 13, 2022

Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen for CLL and SLL at EHA 2022

Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen...

June 13, 2022

AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at EHA 2022

AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at...

June 10, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us